Literature DB >> 15930999

Role of fibroblast growth factor 23 in health and in chronic kidney disease.

Masafumi Fukagawa1, Tomoko Nii-Kono, Junichiro J Kazama.   

Abstract

PURPOSE OF REVIEW: This review summarizes the molecular properties and biological roles of a new phosphaturic factor, fibroblast growth factor 23 (FGF23). Significant roles of FGF23 are discussed, especially in terms of its effects on the kidney, the main target organ. RECENT
FINDINGS: FGF 23 is a recently discovered phosphaturic factor. Several animal experiments including overexpression or ablation of the FGF23 gene have recently revealed the significant effects of this factor on phosphate excretion and on vitamin D synthesis in the kidney. Although FGF23 was originally identified as a factor responsible for several hypophosphatemic disorders, recent data indicate its role in the physiological regulation of phosphate homeostasis. In chronic kidney disease, FGF23 plays a crucial role in the pathogenesis of secondary hyperparathyroidism. Effects of FGF23 on other organs including bone and intestine remain to be elucidated.
SUMMARY: FGF23 is a physiological regulator of phosphate homeostasis. Excessive activity of FGF23 with normal renal function results in hypophosphatemia, low 1,25-dihydroxyvitamin D levels, and rickets/osteomalacia. By contrast, excessive FGF23 activity suppresses 1,25-dihydroxyvitamin D synthesis, but may not be sufficient to excrete the phosphate load appropriately with deteriorating renal function, both of which contribute to the development of hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930999     DOI: 10.1097/01.mnh.0000172717.49476.80

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  13 in total

Review 1.  Does FGF23 toxicity influence the outcome of chronic kidney disease?

Authors:  Mohammed Shawkat Razzaque
Journal:  Nephrol Dial Transplant       Date:  2008-11-07       Impact factor: 5.992

2.  Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease.

Authors:  Sridevi Devaraj; Catherine Duncan-Staley; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2010-08-13       Impact factor: 1.894

Review 3.  From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.

Authors:  Djalila Mekahli; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2013-01-24       Impact factor: 3.714

Review 4.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 5.  FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?

Authors:  M Shawkat Razzaque
Journal:  Am J Physiol Renal Physiol       Date:  2008-11-19

Review 6.  Vitamin D and aging: old concepts and new insights.

Authors:  Beate Lanske; M Shawkat Razzaque
Journal:  J Nutr Biochem       Date:  2007-05-24       Impact factor: 6.048

Review 7.  Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Authors:  Justine Bacchetta; Isidro B Salusky; Martin Hewison
Journal:  Pediatr Nephrol       Date:  2012-11-02       Impact factor: 3.714

8.  Impact of FGF23 level on calcium and phosphorus levels in post-renal transplantation.

Authors:  Fereshteh Saddadi; Aida Rasoolzadeh; Mohammadreza Ganji; Maryam Miri
Journal:  J Renal Inj Prev       Date:  2016-09-03

9.  FGF-23 Levels before and after Renal Transplantation.

Authors:  Domniki Economidou; Spyros Dovas; Aikaterini Papagianni; Panagiotis Pateinakis; Dimitrios Memmos
Journal:  J Transplant       Date:  2009-05-17

Review 10.  Nuclear receptors of the enteric tract: guarding the frontier.

Authors:  Daniel R Schmidt; David J Mangelsdorf
Journal:  Nutr Rev       Date:  2008-10       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.